NEEDHAM, MA--(Marketwired - June 02, 2016) - Insight Pharma Reports, a division of Healthtech Publishing, provides the life science sciences community the report entitled: Liquid Biopsy: An Emerging Market for Radically Improved Cancer Management. This reports deals with recent progress and new directions in this highly dynamic emerging modality for cancer research and in vitro diagnostics.

The Liquid Biopsy: An Emerging Market for Radically Improved Cancer Management focuses on:

• Historical and evolutionary aspects of liquid biopsy, along with background material to aid in understanding the material to follow.
• Recent basic research activities and results, is arranged according to the three sample categories that dominate liquid biopsy today: circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), and extracellular vesicles (EVs, also known as exosomes).
• Commercial activity in each of the aforementioned categories.
• Liquid biopsy from the perspective of market dynamics, and covers: market size estimates along with five-year projections by application segment; the competitive environment; deal activity; and results from an extensive market survey.
• Examines some developing trends in liquid biopsy, and the final chapter presents complete transcripts of interviews.

Experts interviewed in the Liquid Biopsy: An Emerging Market for Radically Improved Cancer Management report include:

• Nicholas Dracopoli, Ph.D., Vice President Oncology Translational Research, Janssen Pharmaceuticals
• Paul Dempsey, Ph.D., Chief Scientific Officer, Cynvenio Biosystems
• Johan Skog, Ph.D., CSO and Founding Scientist, Exosome Diagnostics
• Lidia Sambucetti, PhD, Sr. Director of Cancer Biology, and Ted Ira, Director of Sales, SRI Biosciences Div.
• Harry Glorikian, Life Sciences Consultant

For more information on these reports visit: InsightPharmaReports.com/Liquid-Biopsy-Report

About Insight Pharma Reports (www.insightpharmareports.com)
Insight Pharma Reports, a division of Healthtech Publishing, is the premier life sciences information provider offering unparalleled coverage of key issues in drug discovery and development. The reports are used by leading pharmaceutical, biotech, diagnostic, and other life science companies to keep abreast of the latest developments in pharmaceutical R&D and their potential applications and business impacts. The reports are written by experts in consulting and industry, and are supported by hundreds of hours of primary and secondary research. Insight Pharma Reports provide comprehensive coverage of salient issues in a concise, well-organized format.

About Healthtech Publishing (www.healthtechpublishing.com)
Healthtech Publishing, a division of Cambridge Healthtech Institute, provides the life science communities with business critical intelligence through research reports and digital news, helping decision makers to gain competitive advantage and make strategic decisions. Our portfolio consists of Insight Pharma Reports' vast research reports collection and three niche digital subscription products: Bio-IT World, Clinical Informatics News and Diagnostics World.